PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Alirocumab

Chanukya Dahagam, Aditya Goud, Abdelhai Abdelqader, Aditya Hendrani, Matthew J. Feinstein, Arman Qamar, Parag H. Joshi, Kristopher J. Swiger, Kathleen Byrne, Renato Quispe, Steven R. Jones, Roger S. Blumenthal, Seth S. Martin

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

In this review, we examine alirocumab (Praluent®), a monoclonal antibody to PCSK9 and its role in reducing LDL-C levels. By comparing the results of various studies and trials we discuss the efficacy and safety of alirocumab. We aim to guide clinicians of the role of alirocumab in clinical practice. Overall, PCSK9 inhibitors are promising new agents in further reducing LDL-C levels in addition to diet and maximally tolerated statin therapy. Long-term outcome studies are currently ongoing and will further delineate the role of PCSK9 inhibitors.

Original languageEnglish (US)
Pages (from-to)149-157
Number of pages9
JournalFuture Cardiology
Volume12
Issue number2
DOIs
StatePublished - Mar 1 2016

Keywords

  • alirocumab
  • evolocumab
  • LDL
  • monoclonal antibodies
  • PCSK9 inhibitors
  • statin intolerance

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Alirocumab'. Together they form a unique fingerprint.

  • Cite this

    Dahagam, C., Goud, A., Abdelqader, A., Hendrani, A., Feinstein, M. J., Qamar, A., Joshi, P. H., Swiger, K. J., Byrne, K., Quispe, R., Jones, S. R., Blumenthal, R. S., & Martin, S. S. (2016). PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Alirocumab. Future Cardiology, 12(2), 149-157. https://doi.org/10.2217/fca.15.88